Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 6Urinary Bladder Neoplasms 2Recurrence 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Lymphoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Anus Neoplasms 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

lutetium Lu 177 dotatate 20Magnetic Resonance Spectroscopy 10pembrolizumab 9Specimen Handling 7Everolimus 7cabozantinib 6Nivolumab 6lenvatinib 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5surufatinib 4amino-acid, glucose, and electrolyte solution 4Capecitabine 4olaparib 3lanreotide 3atezolizumab 3Temozolomide 3Octreotide 3Lutetium-177 3Ipilimumab 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2X-Rays 2Radiotherapy 2Phantoms, Imaging 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × entinostat × 1 year × Clear all
NCT03211988 2026-03-02

Entinostat Neuroendocrine (NE) Tumor

Columbia University

Phase 2 Terminated
5 enrolled 9 charts
EndocrineNET

Recurrence, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡